A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128
This study is recruiting at 10 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- MTAP-deleted Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bayer
- Last updated on ClinicalTrials.gov
- September 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's · Denver, CO
Florida · 1
- Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona · Orlando, FL
Massachusetts · 2
- Dana-Farber Cancer Institute - Oncology Department · Boston, MA
- Massachusetts General Hospital - Neurology · Boston, MA
Michigan · 1
- START | Midwest · Grand Rapids, MI
New York · 1
- Memorial Sloan Kettering Cancer Center New York - Main Campus · New York, NY
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 2
- NEXT Dallas - Oncology Department · Irving, TX
- START | San Antonio · San Antonio, TX
Wisconsin · 1
- Froedtert Hospital - Clinical Cancer Center · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.